FindTrial
Sign In

Safety of regional citrate anticoagulation strategy for continuous renal replacement therapy in patients with hepatic insufficiency

Safety of regional citrate anticoagulation strategy for continuous renal replacement therapy in patients with hepatic insufficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057272
Enrollment
Unknown
Registered
2022-03-05
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic insufficiency

Interventions

None listed

Sponsors

The People's Hospital of Linxia
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Liver insufficiency; 2. Regional citrate anticoagulation strategy for continuous renal replacement therapy; 3. Age > 18 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. End-stage liver disease.

Design outcomes

Primary

MeasureTime frame
Serum creatinine, CCr;Total calcium;Free calcium;Lactate;Serum total bilirubin;—

Countries

China

Contacts

Public ContactHuyong Yang

The People's Hospital of Linxia

595617336@qq.com+86 13993075717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026